AGENUS INC (AGEN)       2.56  -0.23 (-8.24%)

2.56  -0.23 (-8.24%)

US00847G7051 - Common Stock - After market: 2.68 +0.12 (+4.69%)

AGENUS INC2.56

NASDAQ:AGEN (12/6/2022, 7:20:22 PM)-0.23 (-8.24%)

After market: 2.68 +0.12 (+4.69%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 02-27 2023-02-27
Ins Owners 0.46% Inst Owners 53.83%
Market Cap 780.32M Shares 304.81M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86
IPO 02-04 2000-02-04

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AGEN Daily chart

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.

Company Info

AGENUS INC

3 Forbes Rd

Lexington MASSACHUSETTS 02421

P: 17816744400.0

CEO: Garo H. Armen

Employees: 441

Website: https://agenusbio.com/

AGEN News

News Image4 days ago - ChartmillThese stocks are moving in today's after hours session

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.

News Image4 days ago - The Motley FoolWhy Shares of Agenus Rose 12.5% on Friday

Agenus presented data this week on a combination therapy.

News Image20 days ago - Agenus Inc.Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of...

News Image20 days ago - Agenus Inc.Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced SarcomaNews Image20 days ago - Market News VideoNoteworthy Wednesday Option Activity: AGEN, PETS, PLCENews Image21 days ago - Agenus Inc.Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and...

AGEN Twits

Here you can normally see the latest stock twits on AGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example